Radiopharmaceuticals developed at the University of Missouri research reactor

Journal Article · Mon Dec 01 04:00:00 EST 1997 · Transactions of the American Nuclear Society

OSTI ID:552708

Ketring, A R; Ehrhardt, G J ^[1]; Day, D E ^[2]

---

1. Univ. of Missouri, Columbia, MO (United States)
2. Univ. of Missouri, Rolla, MO (United States)

The University of Missouri Research Reactor (MURR) has put a great deal of effort in the last two decades into development of radiotherapeutic beta emitters as nuclear medicine radiotherapeutics for malignancies. This paper describes the development of two of these drugs, {sup 153}Sm ethylenediaminetetra-methylene phosphonic acid (EDTMP) (Quadramet{trademark}) and {sup 90}Y glass microspheres (TheraSphere{trademark}). Samarium-153 EDTMP is a palliative used to treat the pain of metastatic bone cancer without the side effects of narcotic pain killers. Yttrium-90 glass microspheres are delivered via hepatic artery catheter to embolize the capillaries of liver tumors and deliver a large radiation dose for symptom palliation and life prolonging purposes.

• OSTI ID: 552708
• Report Number(s): CONF-971125--
• Journal Information: Transactions of the American Nuclear Society, Journal Name: Transactions of the American Nuclear Society Vol. 77; ISSN 0003-018X; ISSN TANSAO
• Country of Publication: United States
• Language: English

Related Subjects

22 GENERAL STUDIES OF NUCLEAR REACTORS
55 BIOLOGY AND MEDICINE
BASIC STUDIES
CAPILLARIES
DESIGN
DRUGS
MICROSPHERES
MURR REACTOR
NUCLEAR MEDICINE
ORGANIC NITROGEN COMPOUNDS
PAIN
PHOSPHONIC ACIDS
RADIOPHARMACEUTICALS
SAMARIUM 153
SIDE EFFECTS
YTTRIUM 90